Wells Pharma of Houston, LLC. v. Zyla Life Sciences, LLC.
Pending Petition
Issue
Whether the Federal Food, Drug, and Cosmetic Act preempts private state-law unfair competition and consumer protection claims premised on the marketing of compounded drugs without premarket approval.
Sep 2, 2025Petition for a writ of certiorari filed. (Response due October 6, 2025)Sep 11, 2025Waiver of right of respondent Zyla Life Sciences, L.L.C. to respond filed.
Sep 17, 2025DISTRIBUTED for Conference of 10/10/2025.
Sep 25, 2025Response Requested. (Due October 27, 2025)
Oct 6, 2025Brief amicus curiae of Americans for Access to Compounded Medication filed.Oct 16, 2025Motion to extend the time to file a response from October 27, 2025 to November 17, 2025, submitted to The Clerk.Oct 20, 2025Motion to extend the time to file a response is granted and the time is extended to and including November 17, 2025.
Oct 27, 2025Brief amicus curiae of Outsourcing Facilities Association filed.Nov 17, 2025Brief of respondent Zyla Life Sciences, L.L.C. in opposition filed.Nov 25, 2025Reply of petitioner Wells Pharma of Houston, L.L.C. filed.Dec 3, 2025DISTRIBUTED for Conference of 1/9/2026.
Jan 12, 2026The Solicitor General is invited to file a brief in this case expressing the views of the United States.
Recommended Citation: Wells Pharma of Houston, LLC. v. Zyla Life Sciences, LLC., SCOTUSblog, https://www.scotusblog.com/cases/wells-pharma-of-houston-llc-v-zyla-life-sciences-llc/